## Dynamics of immature mAb glycoform secretion during CHO cell culture - DTU Orbit (08/11/2017)

## Dynamics of immature mAb glycoform secretion during CHO cell culture: An integrated modelling framework

Ensuring consistent glycosylation-associated quality of therapeutic monoclonal antibodies (mAbs) has become a priority in pharmaceutical bioprocessing given that the distribution and composition of the carbohydrates (glycans) bound to these molecules determines their therapeutic efficacy and immunogenicity. However, the interaction between bioprocess conditions, cellular metabolism and the intracellular process of glycosylation remains to be fully understood. To gain further insight into these interactions, we present a novel integrated modelling platform that links dynamic variations in mAb glycosylation with cellular secretory capacity. Two alternative mechanistic representations of how mAb specific productivity (qp) influences glycosylation are compared. In the first, mAb glycosylation is influenced by variations in Golgi volume. Within our modelling framework, both mechanisms accurately reproduce experimentally-observed dynamic changes in mAb glycosylation enzymes required to minimise mAb glycoform variability. Our results suggest that the availability of glycosylation machinery relative to cellular secretory capacity may play a crucial role in mAb glycosylation. In the future, the modelling framework presented here may aid in selecting and engineering cell lines that ensure consistent mAb glycosylatio.

## **General information**

State: Published Organisations: Department of Systems Biology, Network Engineering of Eukaryotic Cell Factories, University College Dublin, Symphogen A/S Authors: Jimenez del Val, I. (Ekstern), Fan, Y. (Intern), Weilguny, D. (Ekstern) Number of pages: 34 Pages: 610-623 Publication date: 2016 Main Research Area: Technical/natural sciences

## **Publication information**

Journal: Biotechnology Journal Volume: 11 Issue number: 5 ISSN (Print): 1860-6768 Ratings: BFI (2017): BFI-level 1 Web of Science (2017): Indexed yes BFI (2016): BFI-level 1 Scopus rating (2016): CiteScore 3.2 SJR 1.29 SNIP 0.969 Web of Science (2016): Indexed yes BFI (2015): BFI-level 1 Scopus rating (2015): SJR 1.172 SNIP 0.874 CiteScore 2.91 Web of Science (2015): Indexed yes BFI (2014): BFI-level 1 Scopus rating (2014): SJR 1.189 SNIP 1.062 CiteScore 2.98 Web of Science (2014): Indexed yes BFI (2013): BFI-level 1 Scopus rating (2013): SJR 1.136 SNIP 1.093 CiteScore 3.01 ISI indexed (2013): ISI indexed yes Web of Science (2013): Indexed yes BFI (2012): BFI-level 1 Scopus rating (2012): SJR 0.944 SNIP 0.957 CiteScore 2.4 ISI indexed (2012): ISI indexed no Web of Science (2012): Indexed yes BFI (2011): BFI-level 1 Scopus rating (2011): SJR 0.785 SNIP 0.726 CiteScore 1.94 ISI indexed (2011): ISI indexed no BFI (2010): BFI-level 1 Scopus rating (2010): SJR 0.787 SNIP 0.798 Web of Science (2010): Indexed yes

BFI (2009): BFI-level 1 Scopus rating (2009): SJR 0.695 SNIP 0.749 BFI (2008): BFI-level 1 Scopus rating (2008): SJR 0.581 SNIP 0.806 Scopus rating (2007): SJR 0.568 SNIP 0.709 Web of Science (2007): Indexed yes Original language: English Dynamic glycosylation model, In silico glycoengineering, CHO cells, Pharmaceutical bioprocessing, Therapeutic protein glycosylation Electronic versions: Val\_et\_al\_2016\_Biotechnology\_Journal.pdf. Embargo ended: 12/02/2017 DOIs: 10.1002/biot.201400663 Source: FindIt Source-ID: 2290229238 Publication: Research - peer-review > Journal article - Annual report year: 2016